These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28143867)

  • 1. Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
    Singer CF; Tan YY; Fitzal F; Steger GG; Egle D; Reiner A; Rudas M; Moinfar F; Gruber C; Petru E; Bartsch R; Tendl KA; Fuchs D; Seifert M; Exner R; Balic M; Bago-Horvath Z; Filipits M; Gnant M;
    Clin Cancer Res; 2017 Jul; 23(14):3676-3683. PubMed ID: 28143867
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer.
    Chen HL; Chen Q; Deng YC
    Medicine (Baltimore); 2021 Nov; 100(44):e27632. PubMed ID: 34871229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
    Kogawa T; Fouad TM; Liu DD; Wu J; Shen Y; Masuda H; Fujii T; Chavez-MacGregor M; Alvarez RH; Hortobágyi GN; Valero V; Ueno NT
    Oncologist; 2016 Jan; 21(1):21-7. PubMed ID: 26659222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
    Choi JH; Jeon CW; Kim YO; Jung S
    Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
    Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.
    van Ramshorst MS; Loo CE; Groen EJ; Winter-Warnars GH; Wesseling J; van Duijnhoven F; Peeters MTV; Sonke GS
    Breast Cancer Res Treat; 2017 Jul; 164(1):99-106. PubMed ID: 28432515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
    Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
    Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.
    Stocker A; Hilbers ML; Gauthier C; Grogg J; Kullak-Ublick GA; Seifert B; Varga Z; Trojan A
    PLoS One; 2016; 11(7):e0159176. PubMed ID: 27463363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
    Foldi J; Mougalian S; Silber A; Lannin D; Killelea B; Chagpar A; Horowitz N; Frederick C; Rispoli L; Burrello T; Abu-Khalaf M; Sabbath K; Sanft T; Brandt DS; Hofstatter EW; Hatzis C; DiGiovanna MP; Pusztai L
    Breast Cancer Res Treat; 2018 Jun; 169(2):333-340. PubMed ID: 29396664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?
    Antolín S; García-Caballero L; Reboredo C; Molina A; Mosquera J; Vázquez-Boquete Á; Gallego R; Santiago MP; Concha Á; Pérez E; Calvo L; García-Caballero T
    Virchows Arch; 2021 Oct; 479(4):853-857. PubMed ID: 33934230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere.
    Panvichian R; Tantiwetrueangdet A; Wongwaisayawan S; Nampoon A; Lertsithichai P; Leelaudomlipi S
    Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):367-74. PubMed ID: 22417858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.
    Page DB; Wen H; Brogi E; Dure D; Ross D; Spinelli KJ; Patil S; Norton L; Hudis C; McArthur HL
    Breast Cancer Res Treat; 2018 Jan; 167(2):547-554. PubMed ID: 28986743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer.
    Varga Z; Tubbs RR; Wang Z; Sun Y; Noske A; Kradolfer D; Bosshard G; Jochum W; Moch H; Öhlschlegel C
    Breast Cancer Res Treat; 2012 Apr; 132(3):925-35. PubMed ID: 21698407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes.
    Xuan Q; Ji H; Tao X; Xu Y; Zhang Q
    Breast Cancer Res Treat; 2015 Apr; 150(3):581-8. PubMed ID: 25762478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry.
    Davies V; Voutsadakis IA
    Cancer Invest; 2020 Feb; 38(2):94-101. PubMed ID: 31977265
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
    González-Santiago S; Saura C; Ciruelos E; Alonso JL; de la Morena P; Santisteban Eslava M; Gallegos Sancho MI; de Luna A; Dalmau E; Servitja S; Ruiz Borrego M; Chacón JI
    Breast Cancer Res Treat; 2020 Nov; 184(2):469-479. PubMed ID: 32876911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
    Cortazar P; Zhang L; Untch M; Mehta K; Costantino JP; Wolmark N; Bonnefoi H; Cameron D; Gianni L; Valagussa P; Swain SM; Prowell T; Loibl S; Wickerham DL; Bogaerts J; Baselga J; Perou C; Blumenthal G; Blohmer J; Mamounas EP; Bergh J; Semiglazov V; Justice R; Eidtmann H; Paik S; Piccart M; Sridhara R; Fasching PA; Slaets L; Tang S; Gerber B; Geyer CE; Pazdur R; Ditsch N; Rastogi P; Eiermann W; von Minckwitz G
    Lancet; 2014 Jul; 384(9938):164-72. PubMed ID: 24529560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
    Kogawa T; Fujii T; Wu J; Harano K; Fouad TM; Liu DD; Shen Y; Masuda H; Krishnamurthy S; Chavez-MacGregor M; Lim B; Murthy RK; Valero V; Tripathy D; Ueno NT
    Oncologist; 2020 Jun; 25(6):e909-e919. PubMed ID: 32003919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.
    Murthy RK; Raghavendra AS; Hess KR; Fujii T; Lim B; Barcenas CH; Zhang H; Chavez-Mac-Gregor M; Mittendorf EA; Litton JK; Giordano SH; Thompson AM; Valero V; Moulder SL; Tripathy D; Ueno NT
    Clin Breast Cancer; 2018 Dec; 18(6):e1283-e1288. PubMed ID: 30077429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.